Mepolizumab in the treatment of bronchial asthma in children
https://doi.org/10.21518/2079-701X-2020-1-81-86
Abstract
Severe bronchial asthma in children remains a serious problem, which is due to the high risk of mortality, side effects of therapy with high doses of glucocorticosteroids, significant consumption of health resources. The article presents modern data on the pathogenetic mechanisms of bronchial asthma, in particular, on the participation of interleukin-5 (IL-5) in the development of eosinophilic inflammation. Research data demonstrate the safety and effectiveness of anti-IL-5 therapy as a supplement to standard treatment for severe eosinophilic BA and its poor control, including in children. Mepolizumab is the most widely researched anti-IL-5-monoclonal drug. It statistically significantly reduces the level of eosinophilia in the organs, target tissues, reduces the frequency of exacerbations and hospitalizations, significantly reduces the need for maintenance therapy with glucocorticosteroids. The high profile of efficacy and safety of mepolizumab obtained as a result of randomized controlled clinical trials makes it a drug of choice in the treatment of children aged 6 and older with severe eosinophilic BA. However, further post-marketing biomarker studies are required to evaluate the response to anti-IL-5 drugs treatment, to determine the optimal duration and long-term effects of treatment, the risk of relapse in case of withdrawal in children with BA, especially those under 12 years of age.
About the Authors
Yu. L. Mizernitskiy
The Research and Clinical Institute for Pediatrics named after Academician Yuri Veltischev of the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Yuriy L. Mizernitskiy - Dr. of Sci. (Med), professor, Honored Worker of Healthcare of the Russian Federation, Head of the Department of Chronic Inflammatory and Allergic Lung Diseases of the Separate Structural Subdivision The Research and Clinical Institute for Pediatrics named after Academician Yuri Veltischev.
2, Taldomskaya St., Moscow, 125412I. M. Mel'nikova
Yaroslavl State Medical University
Russian Federation
Russian Federation
Irina M. Mel’nikova - Dr. of Sci. (Med), professor, head of the Department of Pediatrics No. 1.
5, Revolutsionnaya St., Yaroslavl, 150000
V. A. Pavlenko
Yaroslavl State Medical University
Russian Federation
Russian Federation
Vasilisa A. Pavlenko, Cand. of Sci. (Med), assistant professor of the Department of Pediatrics No. 1.
5, Revolutsionnaya St., Yaroslavl, 150000
References
1. BatozhargaLova B.T, Mizernitsky Y.L., PodoLnaya M.A. Meta-anaLysis of the prevaLence of asthmaLike symptoms and asthma in Russia (according to the resuLts of ISAAC). Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2016;61(4):59-69. (In Russ.) doi: 10.21508/1027-4065-2016-61-4-59-69.
2. ChuchaLin A.G., Geppe N.A., KoLosova N.G., Kondyu-rina E.G., MaLakhov A.B., Mizernitskiy Yu.L., Revyakina V.A. (eds.) National program: Bronchial Asthma in Children. Treatment Strategy and Prevention. Moscow: OriginaL-maket; 2017. 160 p. (In Russ.). AvaiLabLe at: http://astgmu.ru/wp-content/upLoads/2018/10/NatsionaLnaya-programma-BA-u-detej.-Strategiya-Lecheniya-i-profiLaktika.pdf.
3. Gupta A., Ikeda M., Geng B., Azmi J., Price R.G., Bradford E.S., Yancey S.W., SteinfeLd J. Longterm safety and pharmacodynamics of mepoLi-zumab in chiLdren with severe asthma with an eosinophiLic phenotype. J Allergy Clin Immunol. 2019;144(5):1336-1342.e7. doi: 10.1016/j.jaci.2019.08.005.
4. GLobaL strategy for asthma management and prevention (GINA). 2018. AvaiLabLe at: https://ginasthma.org/wp-content/upLoads/2018/04/wms-GINA-2018-report-V1.3-002.pdf.
5. Johnson N., Varughese B., De La Torre M.A. et aL. Review of Respiratory BioLogic Agents in Severe Asthma. Cureus. 2019;11(9):e5690. doi: 10.7759/cureus.5690.
6. Bochner B.S. The eosinophiL: For better or worse, in sickness and in heaLth. Ann Allergy Asthma Immunol. 2018;121(2):150-155. doi: 10.1016/j.anai.2018.02.031.
7. Kay A.B. The earLy history of the eosinophiL. Clin Exp Allergy. 2015;45(3):575-582. doi: 10.1111/cea.12480.
8. Simon H.U., Yousefi S., Germic N. et aL. The CeLLuLar Functions of EosinophiLs: CoLLegium InternationaLe ALLergoLogicum (CIA). Int Arch Allergy Immunol. 2019;181(1):1-13. doi: 10.1159/000504847.
9. Jatakanon A., Lim S., Barnes PJ. Changes in sputum eosinophiLs predict Loss of asthma controL. Am J Respir Crit Care Med. 2000;161(1):64-72. doi: 10.1164/ajrccm.161.1.9809100.
10. Hakansson K.EJ., Rasmussen LJ.H., Godtfredsen N.S. et aL. The biomarkers suPAR and bLood eosinophiLs are associated with hospitaL readmissions and mortaLity in asthma - a retrospective cohort study. Respir Res. 2019;(20):258. doi: 10.1186/s12931-019-1234-4.
11. Kay A.B., Phipps S., Robinson D.S. A roLe for eosinophiLs in airway remodeLLing in asthma. Trends Immunol. 2004;25(9):477-482. doi: 10.1016/j.it.2004.07.006.
12. Gupta A., PouLiquen I., Austin D. et aL. Subcutaneous mepoLizumab in chiLdren aged 6 to 11 years with severe eosinophiLic asthma. Pediatr Pulmonol. 2019;54(12):1957-1967. doi: 10.1002/ppuL.24508.
13. Sehmi R., Wood LJ., Watson R. et aL. ALLergen-induced increases in IL-5 receptor aLpha-subunit expression on bone marrow-derived CD34+ ceLLs from asthmatic subjects. A noveL marker of progenitor ceLL commitment towards eosinophiLic differentiation. J Clin Invest. 1997;100(10):2466-2475. doi: 10.1172/JCI119789.
14. Pavord I.D., Korn S., Howarth P. MepoLizumab for severe eosinophiLic asthma (DREAM): a muLticentre, doubLe-bLind, pLacebo-controLLed triaL. The Lancet. 2012;(380):651-659. doi: 10.1016/S0140-6736(12)60988-X.
15. SpergeL J.M., Rothenberg M.E., CoLLins M.H. et aL. ResLizumabin chiLdren and adoLescents with eosinophiLic esophagitis: resuLts of a doubLebLind, randomized, pLacebo-controLLed triaL. J Allergy Clin Immunol. 2012;129(2):456-463. doi: 10.1016/j.jaci.2011.11.044.
16. Ruzhitskaya E.A., Vinogradova T.V., Semyonov A.V., Pampura A.N., Treneva M.S., Sukhorukov V.S. Cytokine secretion in chiLdren with eosino-phiLia. Rossijskij vestnik perinatologii i pediatrii = Russian Bulletin of perinatology and pediatrics. 2015;(2):29-36. (In Russ.) AvaiLabLe at: https://www.ped-perinatoLogy.ru/jour/issue/view-FiLe/6/8.
17. Sazonov A.Eh., Petrovskiy F.I., Ivanchuk I.I. et aL. Expression of mRNA membrane-anchored and soLubLe isoforms of receptor of interLeukin-5 a-subunit in induced sputum and peripheraL bLood in patients with bronchiaL asthma. Byulleten’ ehksperimental’noy biologii i meditsiny = Bulletin of experimental biology and medicine. 2003;135(4):437-440. (In Russ.) AvaiLabLe at: https://cyberLeninka.ru/articLe/n/ekspressiya-mrnk-membranosvyazannoy-i-rastvorimoy-izo-form-subedinitsy-retseptora-interleykina-5-v-indutsirovannoy-mokrote-i.
18. Ivanchuk I.I., Ogorodova L.M., Sazonov A.Eh., Leshcheva I.S. et al. Effect of recombinant interleukin-5 on apoptotic death of eosinophils of peripheral blood in patients with bronchial asthma. Meditsinskaya Immunologiya = Medical Immunology. 2004;6(1-2):117-120. (In Russ.) Available at: https//cyberleninka.ru/article/n/vliyanie-rekombinantnogo-interleykina-5-na-apoptoticheskuyu-gibel-eo3inofilov-periferich-eskoy-krovi-bolnyh-bronhialnoy-astmoy.
19. Ruzhitskaya E.A., Minenkova T.A., Mizernitskiy Yu.L. et al. Correlation of cytokine status and eosinophilia in children with allergic bronchopulmonary diseases. Vestnik Novosibirskogo gosudarstvennogo universiteta. Seriya: Biologiya, klin. Meditsina = Journal of the Novosibirsk State University. Series: Biology, clinical medicine. 2012;10(4):89-94. (In Russ.) Available at: https://lib.nsu.ru/xmlui/handle/nsu/5123.
20. Sazonov A.Eh., Ivanchuk I.I., Popova I.S. et al. Expression of mRNA of membrane-bound and soluble isoforms of alpha-subunit of interleukin-5 receptor induced sputum and peripheral blood of bronchial asthma patients. Byulletens sibirskoy meditsiny = Bulletin of Siberian Medicine. 2005;(1):41-44. (In Russ.) Available at: https//elibrary.ru/item.asp?id=12161176/
21. Pelaia C., Vatrella A., Busceti M.T. et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepoli-zumab. Drug Des Devel Ther. 2017;(11):3137-3144. doi: 10.2147/DDDT.S150656.
22. Selby L., Saglani S. Severe asthma in children: therapeutic considerations. Curr Opin Allergy Clin Immunol. 2019;19(2):132-140. doi: 10.1097/ACI.0000000000000521.
23. Farne H.A., Wilson A., Powell C. et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;(9):CD010834. doi: 10.1002/14651858.CD201601.
24. Haldar P., Brightling C.E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009;(360):973-984. doi: 10.1056/NEJMoa0808991.
25. Leckie MJ., ten Brinke A., Khan J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144-2148. doi: 10.1016/S0140-6736(00)03496-6.
26. Buttner C., Lun A., Splettstoesser T. et al. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J. 2003;21(5):799-803. doi: 10.1183/09031936.03.00027302.
27. Flood-Page P, Swenson C., Faiferman I. et al. A study to evaluate safety and efficacy of mepoli-zumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062-1071. doi: 10.1164/rccm.200701-085OC.
28. Powell C., Milan SJ., Dwan K. et al. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev. 2015;27(7):CD010834. doi: 10.1002/14651858.CD010834.pub2.
29. Giovannini M., Mori F. Barni S. et al. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children:how to choose? Ital J Pediatr. 2019;45(1):151. doi: 10.1186/s13052-019-0737-4.
30. Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;(371):1198-1207. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa1403290.
31. Bel E.H., Wenzel S.E., Thompson PJ. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-1197. Available at: https//www.nejm.org/doi/full/10.1056/NEJMoa1403291.
32. Hilvering B., Xue L., Pavord I.D. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. Ther Adv Respir Dis. 2015;9(4):135-145. doi: 10.1177/1753465815581279.
33. Deeks E.D. Mepolizumab: A Review in Eosinophilic Asthma. BioDrugs. 2016;30(4):361-370. Available at: https://link.springer.com/arti-cle/10.1007/s40259-016-0182-5.
34. Albers F.C., Papi A., Taille C. et al. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respir Res. 2019;20(1):169. doi: 10.1186/s12931-019-1134-7.
35. Varricchi G., Canonica G.W. The role of interleukin 5 in asthma. Expert Rev Clin Immunol. 2016;12(9):903-905. doi: 10.1080/1744666X.2016.1208564.
36. Schwarz C., Muller L., Lau S. et al. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood. Pediatr Allergy Immunol. 2018;29(1):28-33. doi: 10.1111/pai.12809.
37. Kurosawa M., Sutoh E. Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients with Severe Eosinophilic Asthma. J InvestigAllergol Clin Immunol. 2019;29(1):40-45. doi: 10.18176/jiaci.0285.
38. Tolkushin A.G., Rogov V.A., Ivanov D.A., Pogudina N.L. Cost-eff ectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma. Kacestvennaa kliniceskaa praktika = Kachestvennaya klinicheskaya praktika. 2019;(1):19-26. (In Russ.) doi: 10.24411/2588-0519-2019-10061.
39. Pertzov B., Unterman A., Shtraichman O. et al. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. J Asthma. 2019;(3):1-6. doi: 10.1080/02770903.2019.1658208.
40. Weir E., Paton JJ. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience. Journal of Asthma. 2019;(22):1-4. doi: 10.1080/02770903.2019.1579833.
41. Cavaliere C., Frati F., Ridolo E. et al. The spectrum of therapeutic activity of mepolizumab. Expert Rev Clin Immunol. 2019;15(9):959-967. doi: 10.1080/1744666X.2019.1656065.
42. Comberiati P, McCormack K., Malka-Rais J. et al. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma. Allergy Clin Immunol Pract. 2019;7(8):2689-2696.e2. doi: 10.1016/j.jaip.2019.05.053.
Review
For citations:
Mizernitskiy YL, Mel'nikova IM, Pavlenko VA. Mepolizumab in the treatment of bronchial asthma in children. Meditsinskiy sovet = Medical Council. 2020;(1):81-86. (In Russ.) https://doi.org/10.21518/2079-701X-2020-1-81-86
Views:
867
Email this article 